Dose calculation of anticancer drugs: A review of the current practice and introduction of an alternative

Journal of Clinical Oncology

Volumn 14, Issue 9, 1996, Pages 2590-2611

  Gurney, H ^a  

^a WESTMEAD HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BUSULFAN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; IFOSFAMIDE; IRINOTECAN; MERCAPTOPURINE; PACLITAXEL; TENIPOSIDE; TOPOTECAN; TRIMETREXATE; VINCRISTINE;

BODY SURFACE; CANCER INHIBITION; CLINICAL TRIAL; DOSE CALCULATION; DOSE RESPONSE; DRUG ABSORPTION; HUMAN; META ANALYSIS; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW;

EID: 0029743058     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.9.2590     Document Type: Review

References (186)

1. Hryniuk WM: The importance of dose intensity in the outcome of chemotherapy. Important Adv Oncol 3:121-141, 1988
2. Gurney H, Dodwell D, Thatcher N, et al: Escalating drug delivery in cancer chemotherapy: A review of concepts and practice -Part 2. Ann Oncol 4:103-115, 1993
3. Gurney H, Dodwell D, Thatcher N, et al: Escalating drug delivery in cancer chemotherapy: A review of concepts and practice Part 1. Ann Oncol 4:23-34, 1993
4. Henderson IC. Hayes DF. Gelman R: Dose-response in the treatment of breast cancer: A critical review. J Clin Oncol 6:1501-1515, 1988
5. Carmo-Pereira J, Costa FO, Henriques E, et al: A comparison of two doses of adriamycin in the primary chemotherapy of disseminated breast carcinoma. Br J Cancer 56:471-473, 1987
6. Samson MK, Rivkin SE, Jones SE, et al: Dose-response and dose-survival advantage for high versus low-dose cisplatin combined with vinblastine and bleomycin in disseminated testicular cancer. A Southwest Oncology Group study. Cancer 53:1029-1035, 1984
7. Frei E III, Canellos GP: Dose: A critical factor in cancer chemotherapy. Am J Med 69:585-594, 1980
8. Piscitelli SC, Rodvold KA, Rushing DA, et al: Pharmacokinetics and pharmacodynamics of doxorubicin in patients with small cell lung cancer. Clin Pharmacol Ther 53:555-561, 1993
9. Preisler HD, Gessner T, Azarnia N, et al: Relationship between plasma adriamycin levels and the outcome of remission induction therapy for acute nonlymphocytic leukemia. Cancer Chemother Pharmacol 12:125-130, 1984
10. 2 the appropriate dosage of busulfan in children undergoing bone marrow transplantation? Blood 79:2475-2479, 1992
11. Rodman JH, Abromowitch M, Sinkule JA, et al: Clinical pharmacodynamics of continuous infusion teniposide: Systemic ex- posuire as a determinant of response in a phase I trial. J Clin Oncol 5:1007-1014, 1987
12. Madden T, Sunderland M, Santana VM, et al: The pharmacokinetics of high-dose carboplatin in pediatric patients with cancer. Clin Pharmacol Ther 51:701-707, 1992
13. Lowis SP, Pearson AD, Newell DR, et al: Etoposide pharmacokinetics in children: The development and prospective validation of a dosing equation. Cancer Res 53:4881-4889, 1993
14. Ratain MJ, Mick R, Schilsky RL, et al: Pharmacologically based dosing of etoposide: A means of safely increasing dose intensity. J Clin Oncol 9:1480-1486, 1991
15. Bennett CL, Sinkule JA, Schilsky RL, et al: Phase I clinical and pharmacological study of 72-hour continuous infusion of etoposide in patients with advanced cancer. Cancer Res 47:1952-1956, 1987
16. Kunitoh H, Watanabe K: Phase l/II and pharmacologic study of long-term continuous infusion etoposide combined with cisplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 12:83-89, 1994
17. Miller AA, Tolley EA, Niell HB, et al: Pharmacodynamics of three daily infusions of etoposide in patients with extensive-stage small-cell lung cancer. Cancer Chemother Pharmacol 31:161-166, 1992
18. Miller AA, Tolley EA, Niell HB, et al: Pharmacodynamics of prolonged oral etoposide in patients with advanced non-small-cell lung cancer. J Clin Oncol 11:1179-1188, 1993
19. Boddy AV, Yule SM, Wyllie R, et al: Pharmacokinetics and metabolism of ifosfamide administered as a continuous infusion in children. Cancer Res 53:3758-3764, 1993
20. Van den Berg HW, Desai ZR, Wilson R, et al: The pharmacokinetics of vincristine in man: Reduced drug clearance associated with raised serum alkaline phosphatase and dose-limited elimination. Cancer Chemother Pharmacol 8:215-219, 1982
21. Moore MJ, Erlichman C, Thiessen JJ, et al: Variability in the pharmaeokinetics of cyclophosphamide, methotrexate and 5-fluorouracil in women receiving adjuvant treatment for breast cancer. Cancer Chemother Pharmacol 33:472-476, 1994
22. Milano G, Roman P, Khater R, et al: Dose versus pharmaeokinetics for predicting tolerance to 5-day continuous infusion of 5-FU. Int J Cancer 41:537-541, 1988
23. Sumiyoshi H, Fujiwara Y, Ohashi N, et al: Clinical pharmacological evaluation of CPT-11 and cisplatin in patients with small cell lung cancer. Proc Am Soc Clin Oncol 14:457, 1995 (abstr 1470)
24. Schellens JHM, Eckardt JR, Creemers GJ, et al: Pharmaeokinetics, clinical pharmacodynamics and safety of chronic oral topotecan in a phase I study. Proc Am Soc Clin Oncol 14:457, 1995 (abstr 1472)
25. Lafolie P, Hayder S, Bjork O, et al: Large interindividual variations in the pharmaeokinetics of oral 6-mercaptopurine in maintenance therapy of children with acute leukaemia and non-Hodgkin lymphoma. Acta Paediatr Scand 75:797-803, 1986
26. Fanucchi MP, Walsh TD, Fleisher M, et al: Phase I and clinical pharmacology study of trimetrexate administered weekly for three weeks. Cancer Res 47:3303-3308, 1987
27. Sonnichsen DS, Hurwitz CA, Pratt CB, et al: Saturable pharmaeokinetics and paclitaxel pharmacodynamics in children with solid tumors. J Clin Oncol 12:532-538, 1994
28. Du Bois D, Du Bois EF: A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med 17:863-871, 1916
29. Gehan EA, George SL: Estimation of human body surface area from height and weight. Cancer Chemother Rep 54:225-235, 1970
30. Gottlieb JA, Gutterman JU, McCredie KB, et al: Chemotherapy of malignant lymphoma with adriamycin. Cancer Res 33:3024-3028, 1973
31. Longo DL, Young RC, Wesley M, et al: Twenty years of MOPP therapy for Hodgkin's disease. J Clin Oncol 4:1295-1306, 1986
32. Marsoni S, Ungerleider RS, Hurson SB, et al: Tolerance to antineoplastie agents in children and adults. Cancer Treat Rep 69:1263-1269, 1985
33. Gelman RS, Tormey DC, Betensky R, et al: Actual versus ideal weight in the calculation of surface area: Effects on dose of 11 chemotherapy agents. Cancer Treat Rep 71:907-911, 1987
34. Williams SD, Birch R, Einhorn LH, et al: Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 316:1435-1440, 1987
35. Fisher RI, Miller TP, Dana BW, et al: Southwest Oncology Group clinical trials for intermediate- and high-grade non-Hodgkin's lymphoma. Semin Hematol 24:21-25, 1987
36. Hartmann O, Benhamou E, Beaujean F, et al: High-dose busulfan and cyclophosphamide with autologous bone marrow transplantation support in advanced malignancies in children: A phase II study. J Clin Oncol 4:1804-1810, 1986
37. Bonadonna G, Brusamolino E, Valagussa P, et al: Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 294:405-410, 1976
38. Perez EA, Coe T, Turrell C, et al: Oral etoposide followed by intravenous taxol: A phase I trial in advanced solid tumours. Proc Am Soc Clin Oncol 14:468, 1995 (abstr 1514)
39. Santoro A, Bonadonna G, Bonfante V, et al: Alternating drug combinations in the treatment of advanced Hodgkin's disease. N Engl J Med 306:770-775, 1982
40. Baker RJ, Kozoli DD, Meyer KA: The use of surface area for establishing normal blood volume. Surg Gynecol Obstet 104:183-189, 1957
41. Smith HW: The Kidney, Structure and Function in Health and Disease. New York, NY, Oxford University, 1951
42. Peters AM, Gordon I, Sixt R: Normalization of glomerular filtration rate in children: Body surface area, body weight or extracellular fluid. J Nucl Med 35:438-444, 1994
43. Schnegg M, Lauterburg BH: Quantitative liver function in the elderly assessed by galactose elimination capacity, aminopyrine demethylation and caffeine clearance. J Hepatol 3:164-171, 1986
44. Lauterburg BH, Preisig R: Quantitation or liver function, in McIntyre N, Benhamou J, Bircher J, et al (eds): Oxford Textbook of Clinical Hepatology. Oxford, United Kingdom, Oxford University, 1991, pp 309-314
45. Crawford JD, Terry ME, Rourke GM: Simplification of drug dosage calculation by application of the surface area principle. Pediatrics 5:783-790, 1950
46. Freireich EJ, Gehan EA, Rall DP, et al: Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep 50:219-231, 1966
47. Goldsmith MA, Slavik M, Carter SK: Quantitative prediction of drug toxicity in humans from toxicology in small and large animals. Cancer Res 35:1354-1364, 1975
48. Pinkel D: The use of body surface area as a criterion of drug dosage in cancer chemotherapy. Cancer Res 18:853-856, 1958
49. Grochow LB, Baraldi C, Noe D: Is dose normalization to weight or body surface area useful in adults? J Natl Cancer Inst 82:323-325, 1990
50. Reilly JJ, Workman P: Normalisation of anti-cancer drug dosage using body weight and surface area: Is it worthwhile? A review of theoretical and practical considerations. Cancer Chemother Pharmacol 32:411-418, 1993
51. Allerheiligen S, Johnson R, Hatcher B, et al: Gemcitabine pharmacokinetics are influenced by gender, body surface area (BSA) and duration of infusion, Proc Am Soc Clin Oncol 13:136, 1994 (abstr 339)
52. Bruno R, Hille D, Thomas L, et al: Population pharmacokinetics/pharmacodynamics (PK/PD) of docetaxel (Taxotere) in phase II studies. Proc Am Soc Clin Oncol 14:457, 1995 (abstr 1471)
53. Vogelzang NJ, Mick R, Janisch L, et al: Phase I and pharmacokinetic study of a new antineoplastic agent: pyrazine diazohydroxide (NSC 361456). Cancer Res 54:114-119, 1994
54. Minami H, Ando Y, Sakai S, et al: Clinical and pharmacologic analysis of hyperfractionated daily oral etoposide. J Clin Oncol 13:191-199, 1995
55. Cosolo WC, Morgan DJ, Seeman E, et al: Lean body mass, body surface area and epirubicin kinetics. Anticancer Drugs 5:293-297, 1994
56. Teresi ME, Riggs CE, Webster PM, et al: Bioequivalence of two methotrexate formulations in psoriatic and cancer patients. Ann Pharmacother 27:1434-1438, 1993
57. Newell DR, Pearson AD, Balmanno K, et al: Carboplatin pharmacokinetics in children: The development of a pediatric dosing formula. The United Kingdom Children's Cancer Study Group. J Clin Oncol 11:2314-2323, 1993
58. Port RE, Daniel B, Ding RW, et al: Relative importance of dose, body surface area, sex, and age for 5-fluorouracil clearance. Oncology 48:277-281, 1991
59. Calvert AH, Newell DR, Gumbrell LA, et al: Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748-1756, 1989
60. Hurwitz CA, Relling MV, Weitman SD, et al: Phase I trial of paclitaxel in children with refractory solid tumors: A Prdiatric Oncology Group study. J Clin Oncol 11:2324-2329, 1993
61. Wiernik PH, Schwartz EL, Einzig A, et al: Phase I trial of Taxol given as a 24-hour infusion every 21 days: Responses observed in metastatic melanoma. J Clin Oncol 5:1232-1239, 1987
62. Dawson WT: Relations between age and weight and dosage of drugs. Ann Intern Med 13:1594-1615, 1940
63. Rodman JH, Relling MV, Stewart CF, et al: Clinical pharmacokinetics and pharmacodynamics of anticancer drugs in children. Semin Oncol 20:18-29, 1993
64. Evans WE, Rodman J, Relling MV, et al: Individualized dosages of chemotherapy as a strategy to improve response for acute lymphocytic leukemia. Semin Hematol 28:15-21, 1991 (suppl 4)
65. McLeod HL, Relling MV, Crom WR, et al: Disposition of antineoplastic agents in the very young child. Br J Cancer 66:23-29, 1992 (suppl 18)
66. Woods WG, O'Leary M, Nesbit ME: Life-threatening neuropathy and hepatotoxicity in infants during induction therapy for acute lymphoblastic leukemia. J Pediatr 98:642-645, 1981
67. Page RL, Macy DW, Thrall DE, et al: Unexpected toxicity associated with use of body surface area for dosing melphalan in the dog. Cancer Res 48:288-290, 1988
68. Arrington KA, Lengendre AM, Simpson-Tabeling G, et al: Comparison of body surface area-based and weight-based dosage protocols for doxorubicin administration in dogs. Am J Vet Res 55:1587-1592, 1994
69. Evans WE, Stewart CF, Chen C, et al: Methotrexate systemic clearance influences probability of relapse in children with standard-risk acute lymphocytic leukaemia. Lancet 1:359-362, 1984
70. Campbell AB, Kaiman SM, Jacobs C: Plasma platinum levels: Relationship to cisplatin dose and nephrotoxicity. Cancer Treat Rep 67:169-172, 1983
71. Ma J, Verweij J, Planting AST, et al: Pharmocokinetic-dynamic relationship of weekly high dose cisplatin in solid tumor patients. Proc Am Soc Clin Oncol 13:133, 1994 (abstr 325)
72. Egorin MJ, Van ED, Tipping SJ, et al: Pharmacokinetics and dosage reduction of cis-diammine(l,l-cyclobutanedicarboxylato)-platinum in patients with impaired renal function. Cancer Res 44:5432-5438, 1984
73. Egorin MJ, Van Echo DA, Olman EA, et al: Prospective validation of a pharmacologically based dosing scheme for the cisdiamminedichloroplatinum(II) analogue diamminecyclobutanedi-carboxylatoplatinum. Cancer Res 44:5432-5438, 1985
74. Herber S, Lennard L, Lilleyman JS, et al: 6-Mercaptopurine: Apparent lack of relation between prescribed dose and biological effect in children with leukaemia. Br J Cancer 46:138-141, 1982
75. Lennard L, Lilleyman JS: Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia. J Clin Oncol 7:1816-1823, 1989
76. Hayder S, Bjork O, Lafolie P: The course of biological parameters and 6-mercaptopurine pharmacokinetics during maintenance treatment of children with acute lymphoblastic leukaemia. Acta Paediatr Scand 79:832-837, 1990
77. Goldberg JA, Kerr DJ, Willmott N, et al: Pharmacokinetics and pharmacodynamics of locoregional 5 fluorouracil (5FU) in advanced colorectal liver metastases. Br J Cancer 57:186-189, 1988
78. Au JL-S, Rustum YM, Ledesma EJ, et al: Clinical pharmacological studies of concurrent infusion of 5-fluorouracil and thymidine in treatment of colorectal carcinomas. Cancer Res 42:2930-2937, 1982
79. Rushing DA, Raber SR, Rodvold KA, et al: The effects of cyclosporineon the pharmacokinetics of doxorubicin in patients with small cell lung cancer. Cancer 74:834-841, 1994
80. Ratain MJ, Rosner G, Duggan D, et al: Population pharmacodynamic study of single-agent doxorubicin in women with stage III breast cancer. Proc Am Soc Clin Oncol 12:140, 1993 (abstr 358)
81. Sasaki Y, Hakusui H, Mizuno S, et al: A pharmacokinetic and pharmacodynamic analysis of CPT-11 and its active metabolite SN-38. Jpn J Cancer Res 86:101-110, 1995
82. Stewart CF, Baker SD, Heideman RL, et al: Clinical pharmacodynamics of continuous infusion topotecan in children: systemic exposure predicts hematologic toxicity. J Clin Oncol 12:1946-1954, 1994
83. Haas NB, LaCreta FP, Walczak J, et al: Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly. Cancer Res 54:1220-1226, 1994
84. Lichtman SM, Ratain MJ, Van ED, et al: Phase I trial of granulocyte-macrophage colony-stimulating factor plus high-dose cyclophosphamide given every 2 weeks: A Cancer and Leukemia Group B study. J Natl Cancer Inst 85:1319-1326, 1993
85. Gianni L, Kearns CM, Giani A, et al: Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 13:180-190, 1995
86. Stoller RG, Hande KR, Jacobs SA, et al: Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. N Engl J Med 297:630-634, 1977
87. Rowinsky EK, Noe DA, Orr DW, et al: Clinical pharmacology of oral and IV N-methylformamide: A pharmacological basis for lack of clinical antineoplastic activity. J Natl Cancer Inst 80:671-678, 1988
88. Egorin MJ, Sigman LM, Van ED, et al: Phase I clinical and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered as a five-day continuous infusion. Cancer Res 47:617-623, 1987
89. Egorin MJ, Van Echo DA, Whitacre MY, et al: Human pharmacokinetics, excretion, and metabolism of the anthracycline antibiotic menogaril (7-OMEN, NSC 269148) and their correlation with clinical toxicities. Cancer Res 46:1513-1520, 1986
90. Desai ZR, Van den Berg H, Bridges JM, et al: Can severe vincristine neurotoxicity be prevented? Cancer Chemother Pharmacol 8:211-214, 1982
91. 2 in children with acute lymphoblastic leukemia. Cancer 60:5-13, 1987
92. Evans WE, Crom WR, Abromowitch M, et al: Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect. N Engl J Med 314:471-477, 1986
93. Rustum YM, Riva C, Preisler HD: Pharmacokinetic parameters of 1-beta-D-arabinofuranosylcytosine (ara-C) and their relationship to intracellular metabolism of ara-C, toxicity, and response of patients with acute nonlymphocytic leukemia treated with conventional and high-dose ara-C. Semin Oncol 14:141-148, 1987 (suppl 1)
94. Milano G, Etienne MC, Schneider M, et al: Pharmacokinetic-pharmacodynamic survey for both fluorouracil and folinic acid during a phase II trial for locally advanced haed and neck carcinoma. Proc Am Soc Clin Oncol 14:460, 1995 (abstr 1483)
95. Milano G, Namer M, Boublil JL, et al: Relationship between systemic 5-FU passage and response in colorectal cancer patients treated with intrahepatic chemotherapy. Cancer Chemother Pharmacol 20:71-74, 1987
96. Ackland SP, Schilsky RL: High-dose methotrexate: A critical reappraisal. J Clin Oncol 5:2017-2031, 1987
97. Erlichman C: Potential applications of therapeutic drug monitoring in treatment of neoplastic disease by antineoplastic agents. Clin Biochem 19:101-106, 1986
98. Ratain MJ, Schilsky RL, Conley BA, et al: Pharmacodynamics in cancer therapy. J Clin Oncol 8:1739-1753, 1990
99. Galpin AJ, Evans WE: Therapeutic drug monitoring in cancer management. Clin Chem 39:2419-2430, 1993
100. Kobayashi K, Jodrell DI, Ratain MJ: Pharmacodynamic-pharmacokinetic relationships and therapeutic drug monitoring. Cancer Surv 17:51-78, 1993
101. Slevin ML, Joel S, Papamichael D, et al: Therapeutic monitoring of infusional etoposide in previously untreated small cell lung cancer. Proc Am Soc Clin Oncol 13:133, 1994 (abstr 328)
102. Stein CA: Suramin: A novel antineoplastic agent with multiple potential mechanisms of action. Cancer Res 53:2239-2248, 1993
103. Eisenberger MA, Sinibaldi VJ, Reyno LM, et al: Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer. J Clin Oncol 13:2174-2186, 1995
104. Kobayashi K, Yokes EE, Vogelzang NJ, et al: Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer. J Clin Oncol 13:2196-2207, 1995
105. Moore MJ, Erlichman C: Therapeutic drug monitoring in oncology. Problems and potential in antineoplastic therapy. Clin Pharmacokinet 13:205-227, 1987
106. Rowinsky EK, Gilbert MR, McGuire WP, et al: Sequences of Taxol and cisplatin: A phase I and pharmacologic study. J Clin Oncol 9:1692-1703, 1991
107. Rowinsky EK, Citardi MJ, Noe DA, et al: Sequence-dependent cytotoxic effects due to combinations of cisplatin and the antimicrotubule agents Taxol and vincristine. J Cancer Res Clin Oncol 119:727-733, 1993
108. Perez EA, Hack F, Fletcher T: Sequence dependent cytotoxicity of Taxol and etoposide in lung and breast human cancer cell lines. Proc Am Soc Clin Oncol 14:491, 1995 (abstr 1604)
109. Maksymiuk AW, Jett JR, Earle JD, et al: Sequencing and schedule effects of cisplatin plus etoposide in small-cell lung cancer: Results of a North Central Cancer Treatment Group randomized clinical trial. J Clin Oncol 12:70-76, 1994
110. Kennedy MJ, Armstrong D, Donehower R, et al: The hematologic toxicity of the Taxol/Cytoxan doublet is sequence dependent. Proc Am Soc Clin Oncol 13:137, 1994 (abstr 342)
111. Gianni L, Straneo M, Capri G, et al: Optimal dose and sequence finding study of paclitaxel by 3 H infusion combined with bolus doxorubicin in untreated metastatic breast cancer patients. Proc Am Soc Clin Oncol 13:74, 1994 (abstr 97)
112. Schellens JHM, Ma J, Bruno R, et al: Pharmacokinetics of cisplatin and Taxotere (docetaxel) and WBC DNA-adduct formation of cisplatin in the sequence Taxotere/cisplatin and cisplatin/Taxotere in a phase I/II study in solid tumor patients. Proc Am Soc Clin Oncol 13:132, 1994 (abstr 323)
113. Rowinsky E, Grochow L, Kaufmann S, et al: Sequence-dependent effects of topotecan and cisplatin in a phase I and pharmacokinetic study. Proc Am Soc Clin Oncol 13:142, 1994 (abstr 361)
114. Huizing MT, van Warmerdam LJC, Rosing H, et al: Pharmacology of dose and sequence finding study of the combination paclitaxel and carboplatin in non-small cell lung cancer. Proc Am Soc Clin Oncol 14:171, 1995 (abstr 367)
115. Sparano JA, Wadler S, Diasio RB, et al: Phase I trial of low- dose, prolonged continuous infusion fluorouracil plus interferon-alfa: Evidence for enhanced fluorouracil toxicity without pharmacokinetic perturbation. J Clin Oncol 11:1609-1617, 1993
116. Epstein RJ: Drug-induced DNA damage and tumor chemosensitivity. J Clin Oncol 8:2062-2084, 1990
117. Plunkett W, Gandhi V: Cellular pharmacodynamics of anticancer drugs. Semin Oncol 20:50-63, 1993
118. Reed E, Ozols RF, Tarone R, et al: Platinum-DNA adducts in leukocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy. Proc Natl Acad Sci USA 84:5024-5028, 1987
119. Reed E, Ostchega Y, Steinberg SM, et at: Evaluation of platinum-DNA adduct levels relative to known prognostic variables in a cohort of ovarian cancer patients. Cancer Res 50:2256-2260. 1990
120. Johnston PG, Lenz HJ, Leichman CG, et al: Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 55:1407-1412, 1995
121. Alberts DS, Chang SY, Chen H-SG, et al: Oral melphaln kinetics. Clin Pharm Ther 26:737-745, 1979
122. Evans WE: Clinical pharmacodynamics of anticancer drugs: A basis for extending the concept of dose-intensity. Blut 56:241-248, 1988
123. Cosolo W, Siderov J, Zalcberg J: Serum methotrexate in childhood ALL. Br J Cancer 66:222, 1992
124. van Warmerdam LJ, ten Bokkel Huinink WW, Macs RA, et al: Limited-sampling models for anticancer agents. J Cancer Res Clin Oncol 120:427-433, 1994
125. Childs WJ, Nicholls EJ, Horwich A: The optimisation of carboplatin dose in carboplatin, etoposide and bleomycin combination chemotherapy for good prognosis metastatic nonseminomatous germ cell tumours of the testis. Ann Oncol 3:291-296, 1992
126. Jodrell DI, Egorin MJ, Canetta RM, et al: Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol 10:520-528, 1992
127. Horwich A, Dearnaley DP, Nicholls J, et al: Effectiveness of carboplatin, etoposide and bleomycin combination chemotherapy in good-prognosis metastatic testicular non seminomatous germ cell tumors. J Clin Oncol 9:62-69, 1991
128. Bonadonna G, Monfardini S, DeLena M, et al: Phase I and prelimanary phase II evaluation of adriamycin (NSC 123, 127). Cancer Res 30:2572-2582, 1970
129. Coltman CA, Luce JK, McKelvey EM, et al: Chemotherapy of non-Hodgkin's lymphoma: 10 years' experience in the Southwest Oncology Group. Cancer Treat Rep 61:1067-1078, 1977
130. Fisher RI, Gaynor ER, Dahlberg S, et al: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N EngI J Med 328:1002-1006, 1993
131. Kobayashi K, Ratain MJ: Individualizing dosing of cancer chemotherapy. Semin Oncol 20:30-42, 1993
132. Arbuck SG, Douglass HO, Crom WR, et al: Etoposide pharmacokinetics in patients with normal and abnormal organ function. J Clin Oncol 4:1690-1695, 1986
133. D'lncalci M, Rossi C, Zucchetti M, et al: Pharmacokinetics of etoposide in patients with abnormal renal and hepatic function. Cancer Res 46:2566-2571, 1986
134. Johnson PJ, Dobbs N, Kalayci C, et al: Clinical efficacy and toxicity of standard dose Adriamycin in hyperbilirubinaemic patients with hepatocellular carcinoma: Relation to liver tests and pharmacokinetic parameters. Br J Cancer 65:751-755, 1992
135. Sulkes A, Collins JM: Reappraisal of some dosage adjustment guidelines. Cancer Treat Rep 71:229-233, 1987
136. Chan KK, Chlebowski RT, Tong M, et al: Clinical pharmacokinetics of adriamycin in hepatoma patients with cirrhosis. Cancer Res 40:1263-1268, 1980
137. Brenner DE, Wiernik PH, Wesley M, et al: Acute doxorubicin toxicity. Cancer 53:1042-1048, 1984
138. Koren G, Beatty K, Seto A, et al: The effects of impaired liver function on the elimination of antineoplastic agents. Ann Pharmacother 26:363-371, 1992
139. Kintzel PE, Dorr RT: Anticancer drug renal toxicity and elimination: Dosing guidelines for altered renal function. Cancer Treat Rev 21:33-64, 1995
140. Perry M: Renal and metabolic toxicities of cancer chemotherapy. Semin Oncol 9:75-83, 1982
141. Gascon MP, Dayer P: Hepatic metabolism of drugs and toxins, in Mclntyre N, Benhamou J, Bircher J, et al (eds): Oxford Textbook of Clinical Hepatology. Oxford, United Kingdom, Oxford University, 1991, pp 247-259
142. Paine AJ: Heterogeneity of cytochrome P450 and its toxicological significance. Hum Exp Toxicol 14:1-7, 1995
143. Evans WE, Relling MV, de Graaf S, et al: Hepatic drug clearance in children: Studies with indocyanine green as a model substrate. J Pharm Sci 78:452-456, 1989
144. Watkins PB, Murray SA, Winkelman LG, et al: Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. Studies in rats and patients. J Clin Invest 83:688-697, 1989
145. Poulsen HE, Loft S: Antipyrine as a model drug to study hepatic drug-metabolizing capacity. J Hepatol 6:374-382, 1988
146. Zhou PX, Seree E, Zhou XJ, et al: Involvement of human liver cytochrome P450 3A in vinblastine metabolism: Drug interactions. Cancer Res 53:5121-5126, 1993
147. Yeh KH, Cheng AL, Chen YC, et al: Unusual neurotoxicity during 24-hour infusion of high-dose 5-fluorouracil and folinic acid in malnutrited hypotriglyceridemic cancer patients. Proc Am Soc Clin Oncol 14:167, 1995 (abstr 351)
148. Tisdale MJ: Cancer cahexia. Anticancer Drugs 4:115-125, 1993
149. Charland SL, Bartlett D, Torosian MH: Effect of proteincalorie malnutrition on methotrexate pharmacokinetics. Jpn J Parenter Enteral Nutr 18:45-49, 1994
150. Dewy s WD, Begg C, Lavin PT, et al: Prognostic effect of weight loss prior to chemotherapy in cancer patients. Am J Med 69:491-497, 1980
151. Reilly JJ, Workman P: Is body composition an important variable in the pharmacokinetics of anticancer drugs? A review and suggestions for further research. Cancer Chemother Pharmacol 34:3-13, 1994
152. Abernethy DR, Greenblatt DJ: Drug disposition in obese humans. An update. Clin Pharmacokinet 11:199-213, 1986
153. Fleming RA, Eldridge RM, Johnson CE, et al: Disposition of high-dose methotrexate in an obese cancer patient. Cancer 68:1247-1250, 1991
154. Powis G, Reece P, Ahmann DL, et al: Effect of body weight on the pharmacokinetics of cyclophosphamide in breast cancer patients. Cancer Chemother Pharmacol 20:219-222, 1987
155. Rodvold KA, Rushing DA, Tewksbury DA: Doxorubicin clearance in the obese. J Clin Oncol 6:1321-1327, 1988
156. Zuccaro P, Guandalini S, Pacifici R, et al: Fat body mass and pharmacokinetics of oral 6-mercaptopurine in children with acute lymphoblastic leukemia. Ther Drug Monit 13:37-41, 1991
157. Baker SD, Grochow LB, Donehower RC: Should anticancer drug doses be adjusted in the obese patient. J Natl Cancer Inst 87:333-334, 1995
158. Georgiadis MS, Steinberg SM, Hankins LA, et al: Obesity and therapy-related toxicity in patients treated for small-cell lung cancer. J Natl Cancer Inst 87:361-366, 1995
159. Stewart CF, Pieper JA, Arbuck SG, et al: Altered protein binding of etoposide in patients with cancer. Clin Pharmacol Ther 45:49-55, 1989
160. Petros WP, Rodman JH, Relling MV, et al: Variability in teniposide plasma protein binding is correlated with serum albumin concentrations. Pharmacotherapy 12:273-277, 1992
161. Claudepierre P, Urien S, Chevalier X, et al: Methotrexate serum binding in rheumatoid arthritis. Int J Clin Pharmacol Ther 32:113-115, 1994
162. Grem JL, Ellenberg SS, King SA, et al: Correlates of severe or life-threatening toxic effects from trimetrexate. J Natl Cancer Inst 80:1313-1318, 1988
163. Igawa M, Ohkuchi T, Ueda M, et al: Factors affecting the outcome of patients with advanced urothelial cancer following chemotherapy with methotrexate, vinblastine, Adriamycin, and cisplatin. Cancer Chemother Pharmacol 30:77-80, 1992 (suppl)
164. Chabner BA, Stoller RG, Hande K, et al: Methotrexate disposition in human case studies in ovarian cancer and following highdose infusion. Drug Metab Rev 1:107-111, 1978
165. Creaven PJ, Mihich E: The clinical toxicity of anticancer drugs and its prediction. Semin Oncol 4:147-163, 1977
166. Egorin MJ: Cancer pharmacology in the elderly. Semin Oncol 20:43-49, 1993
167. Borkowski JM, Duerr M, Donehower RC, et al: Relation between age and clearance rate of nine investigation al anticancer drugs from phase I pharmacokinetic data. Cancer Chemother Pharmacol 33:493-496, 1994
168. Greenblatt DJ, Abernethy DR, Shader RI: Pharmacokinetic aspects of drug therapy in the elderly. Ther Drug Monit 8:249-255, 1986
169. Raveendran R, Heybroek WM, Caulfield M, et al: Protein binding of indomethacin, methotrexate and morphine in patients with cancer. Int J Clin Pharmacol Res 12:117-122, 1992
170. Stewart CF, Fleming RA, Germain BF, et al: Aspirin alters methotrexate disposition in rheumatoid arthritis patients. Arthritis Rheum 34:1514-1520, 1991
171. Cagoni PJ, Matthes S, Dufton C, et al: Ondansetron significantly reduces the area under the curve of cyclophosphamide and cisplatin. Proc Am Soc Clin Oncol 14:462, 1995 (abstr 1489)
172. Boddy AV, Idle JR: The role of pharmacogenetics in chemotherapy: Modulation of tumour response and host toxicity. Cancer Surv 17:79-104, 1993
173. Ratain MJ, Mick R, Berezin F, et al: Phase I study of amonafide dosing based on acetylator phenotype. Cancer Res 53:2304-2308, 1993 (suppl 10)
174. Relling MV, Lin JS, Ayers GD, et al: Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activities. Clin Pharmacol Ther 52:643-658, 1992
175. Evans WE, Relling MV, Rahman A, et al: Genetic basis fora lower prevalence of deficient CYP2D6 oxidative drug metabolism phenotypes in black Americans. J Clin Invest 91:2150-2154, 1993
176. Relling MV, Fairclough D, Ayers D, et al: Patient characteristics associated with high-risk methotrexate concentrations and toxicity. J Clin Oncol 12:1667-1672, 1994
177. Meanwell CA, Blake ARE, Kelly KA, et al: Prediction of ifosfamide/mesna associated encephalopathy. Eur J Cancer Clin Oncol 22:815-819, 1986
178. Von Hoff DD, Sandbach JF, Clark GM, et al: Selection of cancer chemotherapy for a patient by an in vitro assay versus a clinician. J Natl Cancer Inst 82:110-116, 1990
179. Carpenter JT, Maddox WA, Laws HL, et al: Favorable factors in the adjuvant therapy of breast cancer. Cancer 50:18-23, 1982
180. Cortes EP, Holland JF, Wang JJ, et al: Amputation and Adriamycin in primary osteosarcoma. N Engl J Med 291:998-1000, 1974
181. Mclntyre OR, Leone L, Pajak TF: The use of intravenous melphalan (L-PAM) in the treatment of multiple myeloma. Blood 52:274, 1978 (suppl 1, abstr)
182. Lokich JL, Ahlgren JD, Gullo JJ, et al: A prospective randomized comparison of continuous infusion fluorouracil with conventional bolus schedule in metastatic colorectal carcinoma: A mid-Atlantic Oncology Program study. J Clin Oncol 7:425-432, 1989
183. Poon MA, O'Connell MJ, Wieand HS, et al: Biochemical modulation of fluorouracil with leucovorin: Confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol 9:1967-1972, 1991
184. Haas CD, Coltman CA, Gottlieb JA, et al: Phase II evaluation of bleomycin. Cancer 38:8-12, 1976
185. Rahmani R, Zhou XJ: Pharmacokinetics and metabolism of vinca alkaloids. Cancer Surv 17:269-281, 1993
186. Gianni L, Munzone E, Capri G, et al: Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 13:2688-2699, 1995